Four new polymorphic forms of suplatast tosilate

Preparation, characterization, and in vivo evaluation of a polymorphic form of valnemulin hydrogen tartrate

We prepared a polymorphic form of valnemulin hydrogen tartrate (Form I) to overcome the instability and irritating odor of valnemulin hydrochloride that affect its use in the production and application of veterinary drugs. The physicochemical properties of Form I were characterized by scanning electron microscopy, X-ray powder diffraction, infrared spectroscopy, differential scanning calorimetry, and thermogravimetric analysis. The results showed the crystal structure and thermal properties of Form I were very different from those of a commercially available form of valnemulin hydrogen tartrate (Form II). Form I and Form II were more stable than valnemulin hydrochloride after storage under irradiation and high humidity conditions, respectively. The solubility of Form I was 2.6 times that of Form II, and Form I was selected for use in pharmaceutical kinetics experiments in vivo. Compared to valnemulin hydrochloride, after oral administration at a dose of 10 mg/kg in pigs, Form I had similar pharmaceutical kinetic behavior but a slightly higher area under the concentration–time curve from time zero to the last measurable concentration. Consequently, Form I should be suitable for the development of simple formulations and be effective in the clinical application of veterinary drugs.

A new polymorphic form of metoprolol succinate

Only one crystal form of metoprolol succinate (Form I) was reported during previous researches and production. In this study, a new polymorph of metoprolol succinate (here named as Form II) was discovered and investigated by X-ray diffraction, thermoanalysis and infrared spectroscopy. The results show its crystal structure and thermal properties are significantly different with Form I. Compared with Form I, Form II exhibits specific diffraction pattern, lower melting temperature and weaker hydrogen bond effect. The thermostability testing suggests Form II is a metastable crystal form and will gradually transform into Form I undergoing treatment of high temperature and humidity. Metastable crystal form generally has better dissolubility than its corresponding stable form. Subsequent measurement also verified that Form II can dissolve in the water more quickly than Form I.

New polymorphs of 9-nitro-camptothecin prepared using a supercritical anti-solvent process

Recrystallization and micronization of 9-nitro-camptothecin (9-NC) has been investigated using the supercritical anti-solvent (SAS) technology in this study. Five operating factors, i.e., the type of organic solvent, the concentration of 9-NC in the solution, the flow rate of 9-NC solution, the precipitation pressure and the temperature, were optimized using a selected OA16 (4(5)) orthogonal array design and a series of characterizations were performed for all samples. The results showed that the processed 9-NC particles exhibited smaller particle size and narrower particle size distribution as compared with 9-NC raw material (Form I), and the optimum micronization conditions for preparing 9-NC with minimum particle size were determined by variance analysis, where the solvent plays the most important role in the formation and transformation of polymorphs. Three new polymorphic forms (Form II, III and IV) of 9-NC, which present different physicochemical properties, were generated after the SAS process. The predicted structures of the 9-NC crystals, which were consistent with the experiments, were performed from their experimental XRD data by the direct space approach using the Reflex module of Materials Studio. Meanwhile, the optimal sample (Form III) was proved to have higher cytotoxicity against the cancer cells, which suggested the therapeutic efficacy of 9-NC is polymorph-dependent.